DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacokinetics of Tamiflu� (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

Information source: University of Michigan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Critically Ill Renal Failure Requiring CVVHD and Oseltamivir; Critically Ill Requiring ECMO and Oseltamivir

Intervention: pharmacokinetic blood sampling (Procedure); pharmacokinetic blood and dialysate sampling (Procedure)

Phase: Phase 4

Status: Completed

Sponsored by: University of Michigan

Official(s) and/or principal investigator(s):
Bruce A Mueller, Pharm.D., Principal Investigator, Affiliation: University of Michigan


Critically ill patients with flu may receive a drug called oseltamivir. They may also receive medical therapies to support their lung function (extracorporeal membrane oxygenation; ECMO) and kidney function (continuous venovenous hemodialysis; CVVHD). CVVHD and ECMO may remove some oseltamivir from the bloodstream. The purpose of this study is to determine how much oseltamivir gets removed by CVVHD or ECMO in critically ill patients.

Clinical Details

Official title: Pharmacokinetics of Tamiflu (Oseltamivir) in Patients Receiving CVVHD and/or ECMO

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Continuous Venovenous Hemodialysis (CVVHD)Oseltamivir Carboxylate Transmembrane Clearance

Oseltamivir Carboxylate Removal by ECMO


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- receiving Continuous Venovenous Hemodialysis (CVVHD) or Extracorporeal Membrane

Oxygenation (ECMO)

- require oseltamivir treatment

- informed consent granted

Exclusion Criteria:

- pregnant

- unable to complete 12 hours of CVVHD or ECMO

- <6 kg body weight

- allergy to oseltamivir

Locations and Contacts

University of Michigan Hospital, Ann Arbor, Michigan 48109, United States
Additional Information

Starting date: October 2009
Last updated: July 17, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017